Pompovaya insulinoterapiya: novye tekhnologii v sovremennoy klinicheskoy praktike


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main purpose of the treatment of diabetes involves an achievement of optimal long-term glycemic control. Therefore, the introduction of effective and safe methods for the “management" of glicemia into clinical practice is critical. From this perspective, insulin pump therapy is one of the most promising areas of modern diabetology. The present review is devoted to the evaluation of clinical efficacy of insulin pumps, and discussion of characteristics of their structure and functioning.

Full Text

Restricted Access

References

  1. Сунцов Ю.И., Болотская Л.Л., Маслова О.В., Казаков И.В. Эпидемиология сахарного диабета и прогноз его распространенности в Российской Федерации // Сахарный диабет 2011. № 1. С. 15-8.
  2. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993;329:977-86.
  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulpho nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998;352:837-53.
  4. Болотова Н.В., Компанией, О.В., Филина Н.Ю., Поляков В.К. Опыт использования помповой инсулинотерапии у детей и подростков с сахарным диабетом 1 типа // Сахарный диабет 2010. № 4. С. 93-96.
  5. Емельянов А.О., Кураева Т.Л., Лаптев Д.Н., Петеркова В.А. Проспективное наблюдение эффективности и безопасности помповой инсулинотерапии у детей и подростков // Сахарный диабет 2010. № 3. С. 143-46.
  6. Bergenstal R.M., Tamborlane W.V., Ahmann A., et al., for the STAR 3 Study Group. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med 2010; 363:311-20.
  7. De Vries J., Snoek F., Kostense P., Masurel N.A. Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients with LongStanding Poor Glycemic Control. Diabetes Care 2002;25:2074-80.
  8. Hendrychova T., Matoulkova P., Vlcek J., Smahelova A. An overview of so far published analyses comparating the effectiveness of the treatment with insulin pump and multiple daily injections in type 1 diabetes mellitus. Vnitr Lek 2012;58:89-93.
  9. Hirsch B., Bode B., Garg S., et al. Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533-38.
  10. Home P.D., Capaldo B., Burrin J.M., et al. A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulindependent diabetic subjects: improved control with CSII. Diabetes Care 1982;5:466-71.
  11. Howard C.Z. The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther 2010;1:10-24.
  12. Karagianni P., Sampanis C., Katsoulis C., et al. Continuous subcutaneous insulin infusion versus multiple daily injections. HIPPOKRATIA 2009;13:93-6.
  13. Matejko B., Cyganek K., Katra B., et al. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud 2011;8:254-58.
  14. Nathan D.M., Lou P., Avruch J. Intensive, conventional and insulin pump therapy in adult type
  15. diabetes. A crossover study. Ann Intern Med 1982;97:31-6.
  16. Retnakaran R., DeVries J.H., Hanaire-Broutin H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections. Modeling predicted benefits in relationship to baseline A1c. Diabetes Care 2005;28:1835-36.
  17. Retnakaran R., Hochman J., DeVries J.H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections. The impact of baseline A1c. Diabetes Care 2004;27:2590-96.
  18. Alemzadeh R., Ellis J.N., Holzum M.K., et al. Beneficial Effects of Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Insulin Regimen Using Insulin Glargine in Type 1 Diabetes. J Pediatr 2004;114:91-5.
  19. Bruttomesso D., Pianta A., Crazzolara D., et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002; 19:628-34.
  20. Jeitler K., Horvath K., Berghold A., et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008;51:941-51.
  21. Schiaffini R., Ciampalini P., Spera S., et al. An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabetes Metab Res Rev 2005;21:347-52.
  22. Doyle E., Weinzimer S., Steffen A., et al. Randomized, Prospective Trail Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion with Multiple Daily Injections Using Insulin Glargine. Diabetes Care 2004; 27:1554-58.
  23. Hanas R., Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatric Diabetes 2006;7:25-31.
  24. Scrimgeour L., Cobry E., McFann K., et al. Improved Glycemic Control After Long-Term Insulin Pump Use in Pediatric Patients with Type 1 Diabetes. Diabetes Technol Ther 2007;9:421 -28.
  25. Sulli N., Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med 2006;23:900-06.
  26. Weinzimer S.A., Ahern J.H., Doyle E.A., et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004;114:1601-605.
  27. Pickup J.C., Kidd J., Burmiston S., Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabete Metab Res Rev 2006;22:232-37.
  28. Hammond P. NICE guidance on insulin pump therapy: time for a re-appraisal? Pract Diabet Int 2005;22:115-16.
  29. Barnard K.D., Lloyd C.E., Skinner T.C. Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes. Diabet Med 2007;24:607-17.
  30. Hoogma R., Hammon P., Gomist R., et al., on behalf of the 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5 nations trial. Diabet Med 2006;23:141-47.
  31. Linkeschova R., Raoul M., Bott U., et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19:746-51.
  32. Nicoucci A., Maione A., Franciosis M., et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008;25:213-20.
  33. Rubin R.R., Peyrot M. STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012;14:143-51.
  34. Boland E.A., Grey M., Oesterle A., et al. Continuous subcutaneous insulin infusion: a new way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22:1779-84.
  35. Deiss D., Hartmann R., Hoeffe J., Kordonouri O. Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy. Pediatr Diabetes 2004;5:117-21.
  36. Norris S.L., Engelgau M.M., Narayan K.M.V. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001;24:561-87.
  37. Ooi H.L., Wu L.L. Insulin pump therapy in children and adolescents with Type 1 Diabetes: improvements in glycemic control and patients' satisfaction - Hospital UKM experience. Med J Malaysia 2011;66:308-12.
  38. Ramachandani N., Ten S., Anhalt H., et al. Insulin Pump Therapy from the Time of Diagnosis of Type 1 Diabetes. Diabetes Technol Ther 2006; 8:663-70.
  39. Raskin P., Bode B.W., Marks J.B., et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-603.
  40. Wainstein J., Metzger M., Boaz M., et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med 2005;22:1037-46.
  41. Monami M., Lamanna C., Marchionni N., Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis. Exp Clin Endocrinol Diabetes 2009;117:220-22.
  42. Herman W.H., Ilg L.L., Johnson S.L., et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28:1568-73.
  43. Pickap J.C., Renard E. Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes. Diabetes Care 2008;31(2):140-45.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies